Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. Show more

955 Chesterbrook Boulevard, Chesterbrook, PA, 19087, United States

https://www.trevena.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

9.501K

52 Wk Range

$0.00 - $1.80

Previous Close

$0.01

Open

$0.01

Volume

Day Range

$0.01 - $0.01

Enterprise Value

24.11M

Cash

13.46M

Avg Qtr Burn

-4.503M

Insider Ownership

0.49%

Institutional Own.

9.98%

Qtr Updated

09/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OLINVYK™ (oliceridine) Details Pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRV250 (Delta receptor agonist) Details Migraines	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRV045 (S1P receptor) Details Epilepsy, Central nervous system illness, Pain	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRV734 (Mu receptor agonist) Details Opioid use disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRV027 (AT1 receptor selective agonist) Details Acute respiratory distress syndrome, Infectious disease, COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.